Abstract:Shu Lian, 1 Xiaodong Xie, 1 Yusheng Lu, 1, 2, * Lee Jia 1, 2, * 1 Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, People's Republic of China; 2 Marine Drug R&D Center, Institute of Oceanography, Minjiang University, Fuzhou, 350108, People's Republic of China *These authors contributed equally to this work Correspondence: Lee Jia Cancer Metastasis Alert and Prevention Center, Fuzhou University, Sunlight Building, 6FL; Science Park, Xueyuan Road, University Town, Fuzhou 350116, Fujian, People's Republic of China Tel +86 591-22867183 Email cmapcjia1234@163.com Yusheng Lu Marine Drug R&D Center, Institute of Oceanography, Minjiang University, Xiyuangong Road, University Town, Fuzhou 350108, Fujian, People's Republic of China Tel +86-591-83760743 Email lu_yu_sheng@126.com The success of cancer immunotherapy on recognition checkpoints for killing cancer cells has raised a great interest of scientists in understanding new and old methods of immunotherapeutic. CD47 (cluster of differentiation 47) is a cell surface glycoprotein and widely expressed on cells, which belongs to the immunoglobulin (Ig) superfamily as a cell membrane receptor which serves in immune therapy. CD47 is an inhibitory receptor expressed on tumor cell surface and interacts with signal receptor protein-alpha (SIPR-α, also named CD172a or SHPS-1) which may escape from immune cells such as macrophage and T cells. Meanwhile, tumor cells express high CD47 protein which may secrete exosomes with high CD47 expression. The high CD47 expression-exosomes could serve the tumor metastasis process and provide transfer convenience for tumors on the microenvironment. CD47 on cancer cells can also affect the migration and invasion of cells. The high CD47 expression on tumor or CTC (circulating tumor cell) surface means the stronger migration and invasion and makes them escape from immune cells for phagocytosis such as T cells, NK (natural killer) cells and macrophage, which could be used for diagnosis and prognosis on cancer patients. Meanwhile, targeting CD47 combined with other biomarkers such as EpCAM (epithelial cell adhesion molecule), CD44, etc on cancer surface could be used to isolate CTCs from patients' blood. In terms of treatment, anti-CD47 antibody combined with another antibody such as anti-PD-L1 (programmed death-ligand 1) antibody or drugs such as rituximab, DOX or oxaliplatin also has better therapeutic effects and antitumor function to tumors. Using nanomaterials as an intermediary for CD47-related immune therapy could greatly increase the therapeutic effect and overcome multiple biological barriers for anti-CD47 antibody in vivo. In this review, we discuss the important role and the function of CD47 in tumor metastasis and also provide a reference for related research. Keywords: CD47, immune therapy, biological target, immune checkpoint

CD49a Targeting Enhances NK Cell Function and Antitumor Immunity

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models

Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies

NK Cell Dysfunction and Checkpoint Immunotherapy

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches

A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma

Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-cell Lymphoma.

Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.

Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy

Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy

NK cell exhaustion and NK-based checkpoint blockade immunotherapy

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade

Is CD47 an Innate Immune Checkpoint for Tumor Evasion?

Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting